Timothy Pigot
Inhibikase TherapeuticsAbout Timothy Pigot
Timothy Pigot is Chief Commercial and Strategy Officer at Inhibikase Therapeutics (IKT), appointed in August 2025, with more than three decades of commercial leadership experience across PAH, cardiopulmonary and cardiovascular markets. He previously served as Chief Commercial Officer at Aerovate Therapeutics (PAH) and Vice President of Marketing at MyoKardia leading launch strategy for mavacamten; earlier roles include commercial leadership at Gilead Sciences and Pfizer; he holds a BS from SUNY Binghamton School of Management . His tenure at IKT begins ahead of the planned Phase 2b IMPROVE-PAH trial for IKT-001, where his mandate centers on pre-commercial strategy and market access in PAH .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Aerovate Therapeutics | Chief Commercial Officer | Not disclosed | Led commercial planning and strategy for PAH candidate AV-101 |
| MyoKardia | Vice President of Marketing | Not disclosed | Led commercial launch strategy for mavacamten (first-in-class cardiac myosin inhibitor) |
| Gilead Sciences | Commercial leadership roles | Not disclosed | Led sales, marketing, and operations in PAH/cardiopulmonary/CNS/oncology franchises |
| Pfizer | Commercial leadership roles | Not disclosed | Led sales, marketing, and operations in PAH/cardiopulmonary/CNS/oncology franchises |
External Roles
No public company board seats or external directorships are disclosed for Pigot in IKT’s appointment press release and management team page .
Fixed Compensation
Not disclosed as of this writing. IKT has not filed an Item 5.02 8‑K detailing Mr. Pigot’s compensation; the November 14, 2025 8‑K furnished only financial results and a press release noting his appointment without compensation terms .
Performance Compensation
Not disclosed for Mr. Pigot. The latest proxy covers fiscal 2024 NEOs (pre-dating Pigot’s August 2025 appointment) and does not include his incentive plan or metrics . IKT maintains a compensation clawback policy compliant with SEC and Nasdaq rules for incentive-based pay tied to financial measures .
Equity Ownership & Alignment
- Beneficial ownership: As of May 1, 2025 (pre-appointment), the proxy’s ownership table does not include Mr. Pigot; no subsequent Form 4s or proxy data were identified that report his holdings .
- Company equity plan features: IKT’s 2020 Equity Incentive Plan permits options, SARs, restricted stock and RSUs; board/comp committee administer vesting and performance conditions; max term generally 10 years .
- Repricing/overhang context: On Oct 9, 2024, the board repriced certain options (subject to shareholder approval obtained Jan 3, 2025); the plan otherwise restricts repricing without shareholder approval, indicating willingness to adjust underwater awards (alignment risk if repeated) .
- Trading and hedging hygiene: IKT has an insider trading policy and allows Rule 10b5‑1 plans; a clawback policy exists for restatements and excess incentive pay .
Employment Terms
Pigot-specific employment agreement (base salary, target bonus, equity grant, severance, and CoC terms) has not been disclosed in SEC filings to date . For context on company practice, a February 2025 executive appointment (President/Head of R&D) included $500,000 base salary, 45% target bonus, 2.81 million stock options with multi-year vesting, and severance of nine months’ salary (12 months in certain CoC scenarios) plus health benefits and bonus provisions—illustrating current severance economics and option-heavy equity mix at IKT (not Pigot-specific) .
| Recent Comparable Executive Terms (Context, not Pigot-specific) | Details |
|---|---|
| Base salary | $500,000 (President/Head of R&D) |
| Target cash bonus | 45% of base salary |
| Equity grants | 2,810,000 stock options with time-based vesting; portion tied to warrant exercise mechanics |
| Severance (no CoC) | 9 months base salary + COBRA contribution; prior-year earned bonus; pro-rated current-year bonus; partial vesting mechanics |
| Severance (within CoC period) | Enhanced: salary multiple, benefits continuation, and bonus provisions per agreement |
Performance & Track Record
- PAH commercialization: Led commercial planning at Aerovate (AV‑101, PAH), directly relevant to IKT‑001’s PAH strategy .
- Cardiovascular launch strategy: Directed mavacamten launch strategy at MyoKardia, demonstrating rare disease/cardiovascular launch expertise transferrable to PAH .
- Large-cap and specialty breadth: Senior commercial roles at Gilead and Pfizer across PAH, cardiopulmonary, CNS, and oncology .
- Current mandate: Support IKT’s Phase 2b IMPROVE‑PAH initiation and pre-commercial strategy planning for IKT‑001 .
Compensation Committee Analysis
- Composition and independence: Compensation committee composed of non-employee directors Dennis Berman (Chair), Amit Munshi, and Arvind Kush; all independent under Nasdaq rules .
- Authority and practices: Oversees executive pay philosophy, approves executive officer compensation, administers equity plans, and may delegate non‑Section 16 grants to officers; written charter posted on IKT website .
Related Party Transactions
The proxy reports no related‑party transactions since January 1, 2023, beyond standard compensation/indemnification arrangements, per the company’s related‑person transaction policy .
Risk Indicators & Red Flags
- Option repricing history: Board-approved option repricing on Oct 9, 2024 (shareholder-approved Jan 3, 2025) raises potential future expectation of relief for underwater grants—watch for any 2025/2026 adjustments affecting Pigot’s prospective awards .
- Executive transition severance: IKT recorded ~$1.0M severance in SG&A for nine months ended Sep 30, 2025 due to senior executive transitions—indicates active leadership reshaping and potential retention risk as new team forms .
- Governance protections: Clawback policy in place; insider trading and Rule 10b5‑1 plan policies reduce trading/optics risk; change‑in‑control discretion under the plan allows acceleration or substitution of awards (could amplify payouts in M&A) .
Investment Implications
- Pay/ownership transparency pending: There is no disclosed base, bonus target, equity grant, or severance for Pigot yet; monitor for an Item 5.02 8‑K or the next DEF 14A to assess pay‑for‑performance alignment, equity mix (options vs. RSUs), vesting schedules, and potential selling pressure windows .
- Likely equity‑heavy incentives: Context from recent executive hires shows option‑heavy grants and standard severance multiples—expect Pigot’s package to emphasize equity leverage tied to PAH milestones, implying alignment but also overhang risk if repricing patterns reappear .
- Execution upside vs. retention risk: Pigot’s PAH and rare-disease launch pedigree is well matched to IKT‑001’s path; however, 2025 severance charges and leadership changes underscore retention/execution risk during scale‑up—watch hiring cadence, insider plan adoptions (10b5‑1), and upcoming trial catalysts to gauge confidence .
Sources: IKT 2025 Proxy (DEF 14A, May 12, 2025) for governance, plan, ownership, and compensation committee disclosures ; IKT 8‑K press releases Aug 14 and Nov 14, 2025 for financials and strategic updates ; IKT press release and management page for Pigot biography and appointment .